SUNNYVALE, Calif., Oct. 2, 2019 /PRNewswire/ -- Cepheid today announced that it has received clearance from the U.S. Food and Drug Administration for Xpert BCR-ABL Ultra for monitoring disease burden ...
AcroMetrix BCR-ABL External Molecular Panel: An Accurate Testing Method for Chronic Myeloid Leukemia
To support the validation and verification of new assays and to challenge the existing assays in oncology testing, Thermo Fisher Scientific launches Thermo Scientific Acrometrix BCR-ABL Panel. The ...
Expression of CD74 by AML blasts and cell lines, and enhanced in vitro cytotoxicity of anti-CD74 antibody after interferon-gamma (IFN-γ) treatment. Background: Current NCCN guidelines recommend ...
FRANKLIN LAKES, N.J. and PORTLAND, Ore., June 2, 2011 /PRNewswire/ -- Medco Health Solutions, Inc. (NYSE: MHS) and MolecularMD Corp. today announce the launch of a personalized medicine program for ...
ARIAD Pharmaceuticals, Inc.Kendra Adams, 617-503-7028orLiza Heapes, 617-621-2315orKatherine Clock, 503-459-4974 and (NASDAQ: ARIA) today announced that MolecularMD has voluntarily withdrawn its ...
The protocol was approved by our institutional ethics committee and the Central Institutional Review Board of Cancer Research UK. Entrants fulfilled all of the following: aged 18 or over, e14a2 ...
FREMONT, Calif., Oct. 17, 2019 /PRNewswire/ -- Thermo Fisher Scientific, the world leader in serving science, today announced the availability of the Thermo Scientific Acrometrix BCR-ABL Panel, its ...
The oncology landscape is rapidly evolving with new biomarker discoveries and potential targeted treatment options. Consequently, the medical community must work together to develop timely and ...
To find new kinase inhibitors that overcome the imatinib resistance in treatment of chronic myeloid leukemia (CML), we synthesized C817, a novel derivative of curcumin, and tested its activities ...
Asuragen will develop international scale calibrators and software reporting tools. Asuragen inked an exclusive agreement with Novartis to develop international scale (IS) calibrators and laboratory ...
Outcomes of Saudi Arabian Patients With Nasopharyngeal Cancer Treated With Primarily Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy We conducted a retrospective review of patients ...
Patrick J. Muraca is president and chief executive cfficer, co-founder and board member of Pittsfield-based Nuclea Biotechnologies. PITTSFIELD — As Nuclea closed out a year of rapid growth, it signed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback